...
首页> 外文期刊>DMW: Deutsche Medizinische Wochenschrift >Percutaneous coronary intervention in addition to optimal medical therapy for stabile coronary artery disease - A systematic review and meta-analysis [Perkutane Koronarintervention zus?tzlich zu optimaler medikament?ser Therapie bei stabiler koronarer Herzkrankheit: Eine systematische übersicht und Meta-Analyse]
【24h】

Percutaneous coronary intervention in addition to optimal medical therapy for stabile coronary artery disease - A systematic review and meta-analysis [Perkutane Koronarintervention zus?tzlich zu optimaler medikament?ser Therapie bei stabiler koronarer Herzkrankheit: Eine systematische übersicht und Meta-Analyse]

机译:经皮冠状动脉介入治疗以及用于稳定冠状动脉疾病的最佳药物治疗-系统评价和荟萃分析

获取原文
获取原文并翻译 | 示例
           

摘要

Objective: We evaluated the effect of percutaneous coronary interventions (PCI) in addition to optimal medical therapy in stable coronary artery disease (CAD). Methods: A systematic literature search was conducted in the online databases MEDLINE, EMBASE etc. in June 2010, updated in February 2013 in MEDLINE and completed by a hand search. Randomized controlled trials (RCT) and systematic reviews of RCT comparing PCI vs. no PCI in stable CAD were identified and evaluated. Results for death, myocardial infarction and angina pectoris of the RCTs using optimal medical therapy were combined with meta-analysis for relative risk (RR). The strength of the evidence was appraised based on GRADE. Results: After evaluation of 7 systematic reviews and 23 RCT 4 RCTs using optimal medical therapy (Betablockers, ASS, Statins in more than 80% and ACE-Inhibitors in more than 50% of patients the study) were identified. No significant difference was found for the risks of death and of myocardial infarction between the alternatives up to 5 years after beginning the therapy. The PCI reduced the proportion of patients with angina pectoris attacks up to 3 years after beginning the therapy, RR= 0,81 (95 % CI: 0,71 to 0,92). The strength of the evidence was appraised as moderate. Conclusion: The use of PCI in addition to optimal medical therapy in stable CAD may reduce the proportion of patients with angina pectoris attacks up to 3 years after beginning the therapy.
机译:目的:我们评估了经皮冠状动脉介入治疗(PCI)以及最佳药物治疗对稳定冠状动脉疾病(CAD)的效果。方法:于2010年6月在在线数据库MEDLINE,EMBASE等中进行了系统的文献检索,并于2013年2月在MEDLINE中进行了更新,并通过手工检索完成。确定并评估了随机对照试验(RCT)和RCT的系统评价,比较了稳定CAD中PCI与非PCI的比较。采用最佳药物治疗的RCT的死亡,心肌梗塞和心绞痛的结果与相对风险(RR)的荟萃分析相结合。证据的强度是根据GRADE评估的。结果:在对7篇系统评价和23篇RCT进行了评估后,使用最佳药物疗法(研究中80%以上的患者使用Betablockers,ASS,他汀类药物和50%以上的ACE抑制剂)被确定。在开始治疗后长达5年的选择之间,死亡和心肌梗塞的风险没有发现显着差异。在开始治疗后长达3年,PCI减少了患有心绞痛发作的患者的比例,RR = 0.81(95%CI:0.71至0.92)。证据的强度被评估为中等。结论:在稳定的CAD中,除最佳药物治疗外,还使用PCI可能会减少开始治疗后3年内患有心绞痛发作的患者的比例。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号